Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

por Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, Tomaso, Emmanuelle di, Sellers, William R., Caponigro, Giordano
Publicado 2020